|
||||||
| Home |
| Find a Clinical Trial |
| Returning Users |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Juvenile Idiopathic Arthritis (SJIA) Studies - G2301/G2305Two studies are currently available for participation, the doctor will help you determine which study is right for you. The purpose of these two studies is to assess the initial and sustained efficacy and safety of a Novartis investigational drug in participants with SJIA having a flare. Both studies contain randomized, double-bind, placebo controlled parts but all subjects will receive the investigational drug at some point. An "investigational drug" is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA)." An "investigational drug" is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3 Participation Duration: Depending on the trial, participant duration will range from 5 weeks with approximately 6 visits to at least 2 years with visits approximately every 4 weeks. Protocol Number: CACZ885G2301/CACZ885G2305 The next step is to see if you (or the participant) meet the basic criteria required for participation in this clinical trial. Please fill out the questionnaire below to see if you (or the participant) may be suitable for the clinical trial. Your answers to these questions are not retained by this system. You must answer the questions below for yourself, or, you must be the legally authorized representative of the potential participant in order to answer the questions on their behalf. If you (or the participant) do not meet the preliminary qualifications, you may search for other clinical trials of interest or sign up to the Mailing List. Answers to all questions are required to determine if you meet the preliminary qualifications for the study.
|